APO Research
Talk to an analyst

APO RESEARCH · REPORT

GLP-1 Agonists for the Treatment of both Diabetes and Obesity

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Outlook and Growth Opportunities 2026

27 December 2025190 pages

Choose your research edition.

Industry ResearchGLP-1 Agonists for the Treatment of both Diabetes and Obesity Industry Research Report 2026103 pages · $2,950 USDIndustry Growth & TrendsGlobal GLP-1 Agonists for the Treatment of both Diabetes and Obesity Industry Growth and Trends Forecast to 203263 pages · $3,450 USDMarket StructureGlobal GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032172 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global GLP-1 Agonists for the Treatment of both Diabetes and Obesity market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for GLP-1 Agonists for the Treatment of both Diabetes and Obesity is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for GLP-1 Agonists for the Treatment of both Diabetes and Obesity is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for GLP-1 Agonists for the Treatment of both Diabetes and Obesity is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the GLP-1 Agonists for the Treatment of both Diabetes and Obesity market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the GLP-1 Agonists for the Treatment of both Diabetes and Obesity market include Novo Nordisk and Eli Lilly among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global GLP-1 Agonists for the Treatment of both Diabetes and Obesity market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of GLP-1 Agonists for the Treatment of both Diabetes and Obesity and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents GLP-1 Agonists for the Treatment of both Diabetes and Obesity revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global GLP-1 Agonists for the Treatment of both Diabetes and Obesity market.

GLP-1 Agonists for the Treatment of both Diabetes and Obesity Segment by Company

Novo Nordisk

Eli Lilly

GLP-1 Agonists for the Treatment of both Diabetes and Obesity Segment by Type

Tirzepatide

Semaglutide

Liraglutide

GLP-1 Agonists for the Treatment of both Diabetes and Obesity Segment by Application

Retail Pharmacies

Hospital and Clinic

Other

GLP-1 Agonists for the Treatment of both Diabetes and Obesity Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global GLP-1 Agonists for the Treatment of both Diabetes and Obesity status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the GLP-1 Agonists for the Treatment of both Diabetes and Obesity key companies, revenue, market share, and recent developments.

3. To split the GLP-1 Agonists for the Treatment of both Diabetes and Obesity breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions GLP-1 Agonists for the Treatment of both Diabetes and Obesity market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify GLP-1 Agonists for the Treatment of both Diabetes and Obesity significant trends, drivers, influence factors in global and regions.

6. To analyze GLP-1 Agonists for the Treatment of both Diabetes and Obesity competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global GLP-1 Agonists for the Treatment of both Diabetes and Obesity market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of GLP-1 Agonists for the Treatment of both Diabetes and Obesity and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of GLP-1 Agonists for the Treatment of both Diabetes and Obesity.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global GLP-1 Agonists for the Treatment of both Diabetes and Obesity industry.

Chapter 3: Detailed analysis of GLP-1 Agonists for the Treatment of both Diabetes and Obesity company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of GLP-1 Agonists for the Treatment of both Diabetes and Obesity in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of GLP-1 Agonists for the Treatment of both Diabetes and Obesity in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Industry Trends Table 2. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Industry Drivers Table 3. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Industry Opportunities and Challenges Table 4. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Industry Restraints Table 5. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Company (US$ Million) & (2021-2026) Table 6. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Share by Company (2021-2026) Table 7. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Company Ranking, (2024-2026) & (US$ Million) Table 8. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Key Company Manufacturing Base & Headquarters Table 9. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Company, Product Type & Application Table 10. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Tirzepatide Table 15. Significant Companies of Semaglutide Table 16. Significant Companies of Liraglutide Table 17. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Type (2021-2026) Table 21. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Retail Pharmacies Table 23. Significant Companies of Hospital and Clinic Table 24. Significant Companies of Other Table 25. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Application (2021-2026) Table 29. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Application (2027-2032) Table 30. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Region (2021-2026) Table 33. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Region (2027-2032) Table 35. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Market Share by Country (2021-2026) Table 38. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Market Share by Country (2027-2032) Table 40. Novo Nordisk Company Information Table 41. Novo Nordisk Business Overview Table 42. Novo Nordisk GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Novo Nordisk GLP-1 Agonists for the Treatment of both Diabetes and Obesity Product Portfolio Table 44. Novo Nordisk Recent Development Table 45. Eli Lilly Company Information Table 46. Eli Lilly Business Overview Table 47. Eli Lilly GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Eli Lilly GLP-1 Agonists for the Treatment of both Diabetes and Obesity Product Portfolio Table 49. Eli Lilly Recent Development Table 50. Research Programs/Design for This Report Table 51. Authors List of This Report Table 52. Secondary Sources Table 53. Primary Sources List of Figures Figure 1. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Product Image Figure 2. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (2021-2032) & (US$ Million) Figure 4. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Tirzepatide Image Figure 8. Semaglutide Image Figure 9. Liraglutide Image Figure 10. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Type (2021-2032) Figure 13. Retail Pharmacies Image Figure 14. Hospital and Clinic Image Figure 15. Other Image Figure 16. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Application (2021-2032) Figure 19. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value (2021-2032) & (US$ Million) Figure 22. North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value (2021-2032) & (US$ Million) Figure 24. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value (2021-2032) & (US$ Million) Figure 28. South America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Tirzepatide
  • Semaglutide
  • Liraglutide
Applications
  • Retail Pharmacies
  • Hospital and Clinic
  • Other
Companies covered
  • Novo Nordisk
  • Eli Lilly

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Dynamics
  1. 2.1 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Industry Trends
  2. 2.2 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Industry Drivers
  3. 2.3 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Industry Opportunities and Challenges
  4. 2.4 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Industry Restraints
3 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market by Company
  1. 3.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Company Revenue Ranking in 2025
  2. 3.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Company (2021-2026)
  3. 3.3 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Company Ranking (2024-2026)
  4. 3.4 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Company Manufacturing Base and Headquarters
  5. 3.5 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Company Product Type and Application
  6. 3.6 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market by Type
  1. 4.1 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Type Introduction
  2. 4.1.1 Tirzepatide
  3. 4.1.2 Semaglutide
  4. 4.1.3 Liraglutide
  5. 4.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value by Type
  6. 4.2.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value by Type (2021-2032)
  8. 4.2.3 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Type (2021-2032)
5 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market by Application
  1. 5.1 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Application Introduction
  2. 5.1.1 Retail Pharmacies
  3. 5.1.2 Hospital and Clinic
  4. 5.1.3 Other
  5. 5.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value by Application
  6. 5.2.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value by Application (2021-2032)
  8. 5.2.3 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Application (2021-2032)
6 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Regional Value Analysis
  1. 6.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value by Region (2021-2032)
  3. 6.2.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value by Region: 2021-2026
  4. 6.2.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value (2021-2032)
  7. 6.3.2 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value (2021-2032)
  10. 6.4.2 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value (2021-2032)
  16. 6.6.2 South America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Country, 2025 VS 2032
7 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Country-level Value Analysis
  1. 7.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value by Country (2021-2032)
  3. 7.2.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value by Country (2021-2026)
  4. 7.2.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Novo Nordisk
  2. 8.1.1 Novo Nordisk Company Information
  3. 8.1.2 Novo Nordisk Business Overview
  4. 8.1.3 Novo Nordisk GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Novo Nordisk GLP-1 Agonists for the Treatment of both Diabetes and Obesity Product Portfolio
  6. 8.1.5 Novo Nordisk Recent Developments
  7. 8.2 Eli Lilly
  8. 8.2.1 Eli Lilly Company Information
  9. 8.2.2 Eli Lilly Business Overview
  10. 8.2.3 Eli Lilly GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Eli Lilly GLP-1 Agonists for the Treatment of both Diabetes and Obesity Product Portfolio
  12. 8.2.5 Eli Lilly Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst